United States · Financial press · Investor's Business Daily
The Big Caveat Behind Bristol Myers' Sales Guidance Boost
Bristol Myers Squibb stock rose Thursday despite a "mixed bag" performance that included a miss from its biggest cancer drug. The post The Big Caveat Behind Bristol Myers' Sales…
Read the full article on Investor's Business Daily Sign in to saveMarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.investors.com)